Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on HARDIDE PLC. We currently have 21 research reports from 2 professional analysts.
|06Apr17 07:00||RNS||Trading Update|
|29Mar17 07:00||RNS||Airbus Global Approved Supplier Status Gained|
|21Feb17 16:45||RNS||Grant of Options|
|20Feb17 12:36||RNS||Result of AGM|
|20Feb17 07:00||RNS||AGM Statement|
|18Oct16 07:00||RNS||Pre-Close Trading Update|
|06Oct16 14:27||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
Small Cap Breakfast
06 Apr 17
EJF Investments— Publication of prospectus from the closed-ended investment company investing in assets benefitting from regulatory and structural change in the financial services sector. To join Specialist Fund Segment of the Main Market | ADES International Holding— Intends to join the Standard List in May raising up to $170m plus a vendor sale. Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa. | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April. | Alpha FX Group— Schedule 1 update from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Raising £30m. Expected market cap £64.2m and admission 7 April. | K3 Capital Group—Schedule 1 update from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Raising £2.1m plus £15.7m vendor sale. Admission due 11 April. | Tufton Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
29 Mar 17
Accsys (AXS): Tricoya consortium structure completed (BUY) | HML Holdings* (HMLH): Acquisition and upgrade (CORP) | Cambridge Cognition* (COG): Old COG with some cool new tricks (CORP) | Transense Technologies* (TRT): Interim results, further payment from GE (CORP) | Hardide* (HDD): Hardide gains Airbus global supplier status approval (CORP) | Omega Diagnostics* (ODX): Regulatory clearance for Malaria test (CORP) | Allergy Therapeutics (AGY): Interims demonstrate strong momentum (BUY)
19 Dec 16
600 GROUP | ACCSYS TECHNOLOGIES | AGGREGATED MICRO POWER HLDGS PLC | ALUMASC GROUP | ANGLO-EASTERN PLANTATIONS | AVINGTRANS PLC | CAPITAL DRILLING LTD | CARCLO | FENNER PLC | FLOWTECH FLUIDPOWER PLC | GLOBAL INVACOM GROUP LTD | GOOCH & HOUSEGO PLC | HARDIDE PLC | HAYWARD TYLER GROUP PLC | IOFINA PLC | M.P.EVANS GROUP | R.E.A. HLDGS PLC | REDT ENERGY PLC | RENOLD | ROBINSON | SOMERO ENTERPRISE INC | SURFACE TRANSFORMS PLC | TRANSENSE TECHNOLOGIES PLC | TRIFAST | ZAMBEEF PRODUCTS
Full-year results, trading starting to turnaround
12 Dec 16
Full-year results are in line with our expectations and offer grounds for some increased optimism as the oil & gas sector (its largest end-customer) shows some signs that it has bottomed out. Progress continues with Airbus component trials and commercial discussions, and the group’s coatings facility in the US is now operational in advance of anticipated growth in North American demand. We make no changes to our 2017 forecasts, with new 2018 forecasts moving closer to breakeven. We retain our existing 2.1p price target, which offers significant upside on oil sector recovery and positive news flow on aerospace and other developments.
Small Cap Breakfast
12 Dec 16
ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.9m. Target date 14 Dec. Expected market cap £15m, with issue price of 167p. RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m
N+1 Singer - Uncovered Gems - Speed Dating Lunch - A Famous Five for the future?
12 Apr 17
On Friday we hosted our third “speed dating” lunch with the management of five very interesting and contrasting companies not under our formal coverage: Be Heard, Byotrol, Gfinity, Oxehealth and Plant Impact. Each company gave a concise and punchy overview of its business and investment case to a group of fund managers, before rapid fire Q&A. Below we summarise our thoughts on each company with more details inside the note, plus some relevant slides. We believe that all five companies are well-managed and well worth a closer look - we intend to repeat this efficient and popular format for engaging with management teams.
Innovate, specialise, integrate, globalise
01 Dec 16
Carclo has refocused investment in its established businesses (Technical Plastics and LED Technologies), where a differentiated offer and long-term relationships with customers provide good earnings visibility and more certainty of a return. This strategy delivered strong revenue and profits growth during H117. This growth appears set to continue, underpinned by long-term relationships with blue-chip customers. We leave our estimates and indicative valuation broadly unchanged and introduce our estimates for FY19.
N+1 Singer - Scapa Group - Ahead of expectations
13 Apr 17
Following a positive H1, the second half has continued in the same vein, meaning that trading is ahead of expectations. We upgraded in October and November 2016 and now expect the results in May to show a further improvement on our forecasts shown below. We would also expect to increase our FY18 forecasts in May with more detail on the outlook for both divisions. The efficiency driven margin improvement in Industrials continues as Rorschach closes, whilst the Healthcare pipeline is also strong and Euromed is integrating well. With ongoing strong momentum, debt low (therefore M&A a likelihood) and increased confidence in FY18 forecasts, we increase our target price to 405p and remain at Buy.
N+1 Singer - Morning Song 12-04-2017
12 Apr 17
Futura Medical (FUM LN) Multiple licensing discussions underway | Low & Bonar (LWB LN) Solid Q1, trading in line | Nuclear options Significant long-term opportunities for UK companies | RhythmOne (RTHM LN) Trading update – profit and cash ahead | Uncovered Gems - Speed Dating Lunch A Famous Five for the future?
Another upward surprise
07 Apr 17
Despite the surprise trading statement of 23 February, which led us to raise our sales forecasts by c 10% and PBT and EPS by c 20-30%, Treatt has yet again upgraded its outlook for FY17, which leads us to raise our EPS forecasts again by c 6-9%. Our fair value increases to 401p (from 350p) as a result. The constant stream of upgrades demonstrates the strength of momentum in the business as the company moves further up the value chain.